Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients

被引：25

作者：

Ochiai, Hiroki ^{[1
,2
]}

Ohishi, Takashi ^{[2
]}

Osumi, Koji ^{[2
]}

Tokuyama, Jo ^{[2
]}

Urakami, Hidejirou ^{[2
]}

Seki, Shikou ^{[2
]}

Shimada, Atsushi ^{[2
]}

Matsui, Akira ^{[2
]}

Isobe, Yoh ^{[2
]}

Murata, Yuya ^{[3
]}

Endo, Takashi ^{[1
]}

Ishii, Yoshiyuki ^{[1
]}

Hasegawa, Hirotoshi ^{[1
]}

Matsumoto, Sumio ^{[2
]}

Kitagawa, Yuko ^{[1
]}

机构：

[1] Keio Univ, Sch Med, Dept Surg, Shinjuku Ku, Tokyo 1608582, Japan

[2] Natl Tokyo Med Ctr, Dept Surg, Tokyo, Japan

[3] Natl Tokyo Med Ctr, Dept Pathol, Tokyo, Japan

来源：

SURGERY TODAY | 2012年 / 42卷 / 02期

基金：

芬兰科学院;

关键词：

Colorectal cancer; Tumor marker; Serum p53 antibody; SQUAMOUS-CELL CARCINOMA; ANTI-P53; ANTIBODIES; MUTATIONS; ACCUMULATION; AUTOANTIBODIES; PREDICTOR; SURVIVAL;

D O I：

10.1007/s00595-011-0044-1

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

We reevaluated the serum p53 antibody (S-p53Ab) ELISA kit, which was approved as a tumor marker of colon cancer in the Japanese Health Insurance System in 2007. S-p53Ab was measured as a tumor marker in 154 colorectal cancer patients, and the results were categorized by clinical and pathological variables. We then compared the positive frequency of S-p53Ab, carcinoembryonic antigen (CEA), and carbohydrate 19-9 (CA19-9). S-p53Ab was positive in 33.1% of the colorectal cancer patients. The positive rate was significantly higher in patients with lymph nodes metastasis (P = 0.025) and lymphatic invasion (P = 0.023). In patients with stage I colorectal cancer, the positive rate of S-p53Ab (23.7%) was significantly higher than that of CEA (5.3%) or CA19-9 (7.9%). The approved kit for S-p53Ab testing was found to be an effective tumor marker of colorectal cancer. The positive rate of S-p53Ab was significantly higher in patients with cancer involvement of the lymphoid tissues. The positive rate of S-p53Ab was higher than that of CEA and CA19-9 in patients with stage I colorectal cancer, suggesting that the S-p53Ab is a useful tumor marker for patients with early-stage disease.

引用

页码：164 / 168

页数：5

共 27 条

[1]

BOSARI S, 1995, AM J PATHOL, V147, P790

[2] p53 autoantibodies in sera of patients with a colorectal cancer and their association to p53 protein concentration and p53 immunohistochemistry in tumor tissue [J].

Broll, R ;

Duchrow, M ;

Oevermann, E ;

Wellm, C ;

Schwandner, O ;

Schimmelpenning, H ;

Roblick, UJ ;

Bruch, HP ;

Windhövel, U .

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2001, 16 (01) :22-27

[3]

Hammel P, 1999, INT J CANCER, V81, P712, DOI 10.1002/(SICI)1097-0215(19990531)81:5<712::AID-IJC7>3.0.CO

[4]

2-0

[5] P53 MUTATIONS IN HUMAN CANCERS [J].

HOLLSTEIN, M ;

SIDRANSKY, D ;

VOGELSTEIN, B ;

HARRIS, CC .

SCIENCE, 1991, 253 (5015) :49-53

[6] ANTIBODIES AGAINST P53 ARE ASSOCIATED WITH POOR-PROGNOSIS OF COLORECTAL-CANCER [J].

HOUBIERS, JGA ;

VANDERBURG, SH ;

VANDEWATERING, LMG ;

TOLLENAAR, RAEM ;

BRAND, A ;

VANDEVELDE, CJH ;

MELIEF, CJM .

BRITISH JOURNAL OF CANCER, 1995, 72 (03) :637-641

[7] INCREASED EXPRESSION OF MUTANT FORMS OF P53 ONCOGENE IN PRIMARY LUNG-CANCER [J].

IGGO, R ;

GATTER, K ;

BARTEK, J ;

LANE, D ;

HARRIS, AL .

LANCET, 1990, 335 (8691) :675-679

[8] Assessment of SMAD4, p53, and Ki-67 alterations as a predictor of liver metastasis in human colorectal cancer [J].

Kawakami, Masayo ;

Yamaguchi, Tatsuro ;

Takahashi, Keiichi ;

Matsumoto, Hiroshi ;

Yasutome, Michiya ;

Horiguchi, Shinichiro ;

Hayashi, Yukiko ;

Funata, Nobuaki ;

Mori, Takeo .

SURGERY TODAY, 2010, 40 (03) :245-250

[9] Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy [J].

Lechpammer, M ;

Lukac, J ;

Lechpammer, S ;

Kovacevic, D ;

Loda, M ;

Kusic, Z .

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2004, 19 (02) :114-120

[10] P53 STATUS AND THE EFFICACY OF CANCER-THERAPY IN-VIVO [J].

LOWE, SW ;

BODIS, S ;

MCCLATCHEY, A ;

REMINGTON, L ;

RULEY, HE ;

FISHER, DE ;

HOUSMAN, DE ;

JACKS, T .

SCIENCE, 1994, 266 (5186) :807-810

← 1 2 3 →